Presbyopia

Allergan announces positive phase 3 topline results for investigational eye drop for the treatment of presbyopia

Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. In GEMINI 1, the primary endpoint was met with a statistically significant greater...